Citations

Showing 10 of 108015 citations.

Use of a novel triple-tracer approach to assess postprandial glucose metabolism
Basu, Rita , Toffolo, Gianna , Basu, Ananda , Shah, Pankaj, Rizza, Robert A., Camillo, Barbara Di , Vella, Adrian , Cobelli, Claudio

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 284 | Issue: 1 | Pages: E55-E69

10.1152/ajpendo.00190.2001 | PMID 12485809 Get It

Numerous studies have used the dual-tracer method to assess postprandial glucose metabolism. The present experiments were undertaken to determine whether the marked tracer nonsteady state that occurs with the dual-tracer approach after food ingestion introduces error when it is used to simultaneously measure both meal glucose appearance (Ra meal) and endogenous glucose production (EGP). To do so, a novel triple-tracer approach was designed: 12 subjects ingested a mixed meal containing [1-13C]glucose while [6-3H]glucose and [6,6-2H2]glucose were infused intravenously in patterns that minimized the change in the plasma ratios of [6-3H]glucose to [1-13C]glucose and of [6,6-2H2]glucose to endogenous glucose, respectively. Ra meal and EGP measured with this approach were essentially model independent, since non-steady-state error was minimized by the protocol. Initial splanchnic glucose extraction (ISE) was 12.9% ± 3.4%, and suppression of EGP (EGPS) was 40.3% ± 4.1%. In contrast, when calculated with the dual-tracer one-compartment model, ISE was higher ( P < 0.05) and EGPS was lower ( P < 0.005) than observed with the triple-tracer approach. These errors could only be prevented by using time-varying volumes different for Ra meal and EGP. Analysis of the dual-tracer data with a two-compartment model reduced but did not totally avoid the problems associated with marked postprandial changes in the tracer-to-tracee ratios. We conclude that results from previous studies that have used the dual-tracer one-compartment model to measure postprandial carbohydrate metabolism need to be reevaluated and that the triple-tracer technique may provide a useful approach for doing so.
Effects of caloric restriction on mitochondrial function and gene transcripts in rat muscle
Sreekumar, R., Unnikrishnan, J., Fu, Aizhong, Barazzoni, Rocco , Nygren, Jonas , Short, Kevin R. , Schimke, Jill M. , Nair, K. Sreekumaran

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 283 | Issue: 1 | Pages: E38-E43

10.1152/ajpendo.00387.2001 | PMID 12067840 Get It

Rodent skeletal muscle mitochondrial DNA has been shown to be a potential site of oxidative damage during aging. Caloric restriction (CR) is reported to reduce oxidative stress and prolong life expectancy in rodents. Gene expression profiling and measurement of mitochondrial ATP production capacity were performed in skeletal muscle of male rats after feeding them either a control diet or calorie-restricted diet (60% of control diet) for 36 wk to determine the potential mechanism of the beneficial effects of CR. CR enhanced the transcripts of genes involved in reactive oxygen free radical scavenging function, tissue development, and energy metabolism while decreasing expression of those genes involved in signal transduction, stress response, and structural and contractile proteins. Real-time PCR measurments confirmed the changes in transcript levels of cytochrome- c oxidase III, superoxide dismutase (SOD)1, and SOD2 that were noted by the microarray approach. Mitochondrial ATP production and citrate synthase were unaltered by the dietary changes. We conclude that CR alters transcript levels of several genes in skeletal muscle and that mitochondrial function in skeletal muscle remains unaltered by the dietary intervention. Alterations in transcripts of many genes involved in reactive oxygen scavenging function may contribute to the increase in longevity reported with CR.
Impact of high-fat diet and antioxidant supplement on mitochondrial functions and gene transcripts in rat muscle
Sreekumar, R., Unnikrishnan, J., Fu, Aizhong, Barazzoni, Rocco , Nygren, Jonas , Short, Kevin R. , Schimke, Jill M. , Nair, K. Sreekumaran

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 282 | Issue: 5 | Pages: E1055-E1061

10.1152/ajpendo.00554.2001 | PMID 11934670 Get It

High-fat diets are reported to increase oxidative stress in a variety of tissues, whereas antioxidant supplementation prevents many diseases attributed to high-fat diet. Rodent skeletal muscle mitochondrial DNA has been shown to be a potential site of oxidative damage. We hypothesized that the effects of a high-fat diet on skeletal muscle DNA functions would be attenuated or partially reversed by antioxidant supplementation. Gene expression profiling and measurement of mitochondrial ATP production capacity were performed in skeletal muscle from male rats after feeding one of three diets (control, high-fat diet with or without antioxidants) for 36 wk. The high-fat diet altered transcript levels of 18 genes of 800 surveyed compared with the control-fed rats. Alterations included reduced expression of genes involved in free-radical scavenging and tissue development and increased expression of stress response and signal transduction genes. The magnitude of these alterations due to high-fat diet was reduced by antioxidant supplementation. Real-time PCR measurements confirmed the changes in transcript levels of cytochrome c oxidase subunit III and superoxide dismutase-1 and -2 noted by microarray approach. Mitochondrial ATP production was unaltered by dietary changes or antioxidant supplemention. It is concluded that the high-fat diet increases the transcription of genes involved in stress response but reduces those of free-radical scavenger enzymes, resulting in reduced DNA repair/metabolism (increased DNA damage). Antioxidants partially prevent these changes. Mitochondrial functions in skeletal muscle remain unaltered by the dietary intervention due to many adaptive changes in gene transcription.
Aminoacyl-tRNA enrichment after a flood of labeled phenylalanine: insulin effect on muscle protein synthesis
Caso, Giuseppe, Ford, G. C., Garlick, Peter J., McNurlan, Margaret A., Nair, K. Sreekumaran

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 282 | Issue: 5 | Pages: E1029-E1038

10.1152/ajpendo.00215.2001 | PMID 11934667 Get It

Muscle protein synthesis in dogs measured by flooding withl-[2H5]phenylalanine (70 mg/kg) was significantly stimulated by infusion of insulin with amino acids. The stimulation of muscle protein synthesis was similar when calculated from the enrichment of phenylalanyl-tRNA (61 ± 10%, P< 0.001), plasma phenylalanine (61 ± 10%, P < 0.001), or tissue fluid phenylalanine (54 ± 10%, P < 0.001). The time course for changes in enrichment ofl-[2H5]phenylalanine throughout the flooding period was determined for plasma, tissue fluid, and phenylalanyl-tRNA in the basal state and during the infusion of insulin with amino acids. Enrichments of plasma free phenylalanine and phenylalanyl-tRNA were equalized between 20 and 45 min, although the enrichment of phenylalanyl-tRNA was lower at early time points. Rates of muscle protein synthesis obtained with the flooding method and calculated from plasma phenylalanine enrichment were comparable to those calculated from phenylalanyl-tRNA and also to those obtained previously with a continuous infusion of phenylalanine with phenylalanyl-tRNA as precursor. This study confirms that, with a bolus injection of labeled phenylalanine, the enrichment of aminoacyl-tRNA, the true precursor pool for protein synthesis, can be assessed from more readily sampled plasma phenylalanine.
Genome Editing as a Tool toward Better Functional Understanding of Variants Identified by Next-Generation Sequencing
Aypar, Umut

Mayo Clinic

Clinical Chemistry | February 27, 2015 | Volume: 61 | Issue: 3 | Pages: 564-565

10.1373/clinchem.2014.235663 | PMID 25874293 Get It

Commentary
Hoyer, James D.

Mayo Clinic

Clinical Chemistry | February 27, 2015 | Volume: 61 | Issue: 3 | Pages: 469-470

10.1373/clinchem.2014.226944 | PMID 25725048 Get It

Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case‐control study
Höfer, R , Ahle, Barrett J., Nkwonta, Jacinta A., Narr, Bradly J., Pardanani, Animesh , Schroeder, Darrell R. , Weingarten, Toby N. , Kemp, Keri M. , Šprung, Juraj , Schroeder, Darrell

Mayo Clinic

Transfusion | February 27, 2015 | Volume: 55 | Issue: 5 | Pages: 1090-1097

10.1111/trf.13006 | PMID 25727411 Get It

BACKGROUNDPatients with polycythemia vera (PV) have historically been considered to be at high risk for perioperative hemorrhagic and thromboembolic complications. However, no recent studies have compared these outcomes between treated PV patients and patients without PV undergoing similar procedures.STUDY DESIGN AND METHODSPatients with PV who underwent surgery with anesthesia from June 1, 2006, to May 31, 2011, were randomly matched (sex, age, type of surgical procedure, surgical year) at a ratio of 1:4 with control patients without PV. Conditional logistic regression analysis adjusting for surgical duration, preoperative hemoglobin, platelet count, and cardiovascular disease was used to assess the association between PV and blood product transfusions, thromboembolism, and other major cardiovascular and pulmonary complications.RESULTSFifty‐six PV patients who underwent 79 surgeries were matched with 312 controls. During hospitalization, 35 (44.3%) and 82 (25.9%) PV and control patients, respectively, were transfused with blood products. PV patients were at increased risk for transfusion intraoperatively (odds ratio [OR], 4.35; 95% confidence interval [CI], 1.79‐10.57; p = 0.001) and during hospitalization (OR, 4.35; 95% CI, 1.84‐10.31; p < 0.001). The likelihood of thromboembolic complications and/or other major complications did not differ between the two study groups (thromboembolic—OR 1.53, 95% CI 0.39‐6.02, p = 0.540; other major complications—OR 2.15, 95% CI 0.93‐4.96, p = 0.073).CONCLUSIONSMedically managed PV patients had an increased likelihood of receiving blood products perioperatively. Given the low number of observed thromboembolic events, we cannot make definitive conclusions regarding the association between PV and thromboembolism.
Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans
Shah, Pankaj, Basu, Rita , Basu, Ananda , Camilleri, Michael , Schwenk, W. Frederick, Rizza, Robert A., Vella, Adrian , Schwenk, W. Frederick

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 283 | Issue: 2 | Pages: E259-E266

10.1152/ajpendo.00178.2001 | PMID 12110530 Get It

To determine if enteral delivery of glucose influences splanchnic glucose metabolism, 10 subjects were studied when glucose was either infused into the duodenum at a rate of 22 μmol · kg −1 · min −1 and supplemental glucose given intravenously or when all glucose was infused intravenously while saline was infused intraduodenally. Hormone secretion was inhibited with somatostatin, and glucose (∼8.5 mmol/l) and insulin (∼450 pmol/l) were maintained at constant but elevated levels. Intravenously infused [6,6- 2 H 2 ]glucose was used to trace the systemic appearance of intraduodenally infused [3- 3 H]glucose, whereas UDP-glucose flux (an index of hepatic glycogen synthesis) was measured using the acetaminophen glucuronide method. Despite differences in the route of glucose delivery, glucose production (3.5 ± 1.0 vs. 3.3 ± 1.0 μmol · kg −1 · min −1 ) and glucose disappearance (78.9 ± 5.7 vs. 85.0 ± 7.2 μmol · kg −1 · min −1 ) were comparable on intraduodenal and intravenous study days. Initial splanchnic glucose extraction (17.5 ± 4.4 vs. 14.5 ± 2.9%) and hepatic UDP-glucose flux (9.0 ± 2.0 vs. 10.3 ± 1.5 μmol · kg −1 · min −1 ) also did not differ on the intraduodenal and intravenous study days. These data argue against the existence of an “enteric” factor that directly (i.e., independently of circulating hormone concentrations) enhances splanchnic glucose uptake or hepatic glycogen synthesis in nondiabetic humans.
Congenital Absence of the Right Pericardium: Embryology and Imaging
Koo, Chi Wan , Newburg, Adrienne

Mayo Clinic

Journal of Clinical Imaging Science | February 27, 2015 | Volume: 5 | Issue: No issue available | Pages: 12

10.4103/2156-7514.152338 | PMID 25861546 Get It

Though congenital pericardial absence is often asymptomatic, complications can be life threatening. To date, few short case reports, primarily from the pre-CT and MR era, describe congenital absence of the right pericardium. We present a more comprehensive discussion of the embryologic derangements causing such defects and offer an up-to-date review of characteristic radiologic findings. Recognition of characteristic imaging findings of congenital pericardial absence is crucial in guiding diagnosis and management.
Tuberculosis as a Force Health Protection Threat to the United States Military
Sánchez, José L. , Sanchez, Joyce L. , Cooper, Michael J. , Hiser, Michelle J., Mancuso, James D.

Mayo Clinic

Military Medicine | February 27, 2015 | Volume: 180 | Issue: 3 | Pages: 276-284

10.7205/milmed-d-14-00433 | PMID 25735017 Get It

ABSTRACT Tuberculosis (TB) is a communicable disease that poses a threat to force health protection to the U.S. military. The rate of TB disease in the military is low; however, there are unique challenges for its control in this setting. As a low-risk population, TB testing in the U.S. military can be scaled back from the universal testing approach used previously. Reactivation of latent TB infection (LTBI) present at accession into service is the most important factor leading to TB disease; therefore, its diagnosis and treatment among recruits should be given a high priority. Deployment and overseas military service is an uncommon but important source of TB infection, and rigorous surveillance should be ensured. Case management of TB disease and LTBI can be improved by the use of cohort reviews at the service and installation levels and case finding and delays in the diagnosis of TB disease can be improved by education of providers, as well as increased use of molecular diagnostic tests. Program outcomes can be improved by making LTBI treatment compulsory, offering shorter treatment regimens, and increasing accountability through oversight and evaluation. The diagnosis of LTBI can be improved by implementing targeted testing in all settings and reducing confirmatory interferon-gamma release assay testing.